Dyax resuming DX-88 trials

DYAX said FDA released the clinical hold on DX-88, allowing the company to resume the Phase II EDEMA2 trial of the recombinant kallikrein inhibitor protein to treat hereditary angioedema (HAE). Last week, FDA placed the trial on hold after sporadic deaths of rats were seen in a toxicology study. ...